The future of cancer treatment and wellness innovation
- Active clinical trials exploring treatment and applications
- Wellness products already generating consumer revenue
- FDA-reviewed ingredients support safe, legal supplement use
- Patent protections secured through 2038
- $75M+ raised from accredited, family office, & institutional investors
And now you can invest in the future of NextGen Scientific.
We are the only company in the world developing the Black Calla Lily into both regulated pharmaceuticals and consumer supplements.
A Timeless Plant
A Personal Mission
In a small village near Jerusalem, a father observed something extraordinary: the Black Calla Lily (Arum Palaestinum), which has been used for generations in traditional healing.
Today, our family story is powering a scientifically-driven platform poised to reshape cancer care and wellness.
$10,009,872
$4.08
Dual Strategy, Single Vision
Genzada Pharmaceuticals
Hyatt Life Sciences
Upcoming Investor Events & News
Inside NextGen Scientific’s Clinical Roadmap: Oncology & Dermatology Programs Explained
Most early-stage biotech is a binary bet. One trial fails, the company fails. NextGen built a different structure: a pharmaceutical pipeline backed by a profitable nutraceutical line that already generates ~$1.7M in annual revenue without spending a dollar on marketing. The numbers worth knowing: → $75M already raised. $10M Reg D 506C round open now. […]
Inside NextGen Scientific: CEO on the Company’s Path to Effective Cancer Treatment.
Inside NextGen Scientific: Innovation, Mission, and the Path to Commercialization
In this webinar conversation, NextGen Scientific’s CEO shares the story behind the company’s breakthrough cancer treatment approach and outlines the vision for advancing the technology toward commercialization.
Explore an Investment Opportunity with $650B+ in Target Markets
